SHANGHAI :
Kangtai Partners With Belgian Desmons to Make DTP-Hib-IPV Vaccine for China
Tang Shihua
DATE:  Nov 12 2018
/ SOURCE:  Yicai
Kangtai Partners With Belgian Desmons to Make DTP-Hib-IPV Vaccine for China Kangtai Partners With Belgian Desmons to Make DTP-Hib-IPV Vaccine for China

(Yicai Global) Nov. 12 -- Chinese jab maker Kangtai Biological Products will team up with Belgian Desmons Consulting to develop a combination vaccine against diphtheria, tetanus, pertussis, as well as polio and Haemophilus influenzae type b for the Chinese market.

Kangtai signed a framework agreement with Desmons Consulting to make the DTP-Hib-IPV drug, the Shenzhen-based pharma firm said in a statement yesterday.

The new vaccine will be in one bottle which is more convenient for use, as well as transport and storing, the statement added. DTP and IPV are currently given separately to all Chinese kids under the national immunization plan. Haemophilus influenzae type b is not part of the compulsory vaccine scheme but is recommended by the World Health Organization.

Kangtai will pay the Nivelles-based medical consultancy sales commissions for the first five years. The firms did not disclose other financial terms of the deal.

Editor: Emmi Laine

Follow Yicai Global on
Keywords:   DESMONS CONSULTING,Kangtai Biological Products